A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 in Patients With Locally Advanced or Metastatic Solid Tumors
What is the purpose of this trial?
This is an open label Phase 1, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic, colon and lung cancers.
- Trial withMabspace Biosciences (Suzhou) Co., Limited
- Start Date03/04/2021
- End Date12/31/2022
- Last Updated07/15/2021
- Study HIC#2000029047